PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness

• Published in: Lung cancer management 2018-06, Vol.7 (2)
• Main Authors: Gkogkozotou, Vasiliki-Konstantina I, Gkiozos, Ioannis C, Charpidou, Andriani G, Kotteas, Elias A, Boura, Paraskevi G, Tsagouli, Sophia N, Syrigos, Konstantinos N
• Format: Article
• Language: English
• Subjects: Accounting; accuracy; Age; Cancer therapies; Cost analysis; Health economics; Lung cancer; Lymphatic system; Medical imaging; Medical prognosis; Metastasis; Mortality; non-small-cell lung cancer (NSCLC); Ostomy; Patients; PET/CT; reliability; staging; Surgery; Systematic review; thoracotomy; Tomography
• ISSN: 1758-1966; 1758-1974
• DOI: 10.2217/lmt-2018-0008

To determine whether PET/CT and brain MRI used in staging NSCLC can be accurate, reliable and cost-effective tools. NSCLC represents 80-85% of lung cancer and adequate information on the initial tumor staging is critical for planning an optimal therapeutic strategy. Data from 30 newly diagnosed NSCLC patients in Greece were collected and prospectively recorded. Patients with potential resectable disease were evaluated to ensure that there are no detectable metastases that would rule out the possibility of a curative surgery. Divergence occurred in 50% of cases of staging with CT or PET/CT alone, while metastases undetectable by the CT were revealed using PET/CT. Unnecessary thoracotomies were avoided by 10% of patients and another 10% was operated on after chemotherapy with a better prognosis. PET/CT and brain MRI combined are reliable for correct staging, reducing avoidable thoracotomies, morbidity rates and costs.